July 21st, 2014
Selections from Richard Lehman’s Literature Review: July 21st
Richard Lehman, BM, BCh, MRCGP
This week’s topics include the effects of extended-release niacin with laropiprant in high-risk patients and dual-antiplatelet beyond one year after DES implantation.
January 15th, 2013
Is HDL Fool’s Gold?
Peter Paul Toth, MD, PhD
Peter P. Toth offers his perspective on recent trials of niacin, including HPS2-THRIVE and AIM-HIGH.
NEJM Journal Watch — Recent Cardiology Articles- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?
- Can Genetic and Social Risk Scores Improve Cardiac Risk Prediction?
- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?
- Are Angiographically-Derived Coronary Physiology Measurements Ready for Use in the Cath Lab?